-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

Benzinga·09/30/2026 18:11:35
Listen to the news
JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.